Ustekinumab ‘might trigger CV events’ in at-risk patients
Caution might be needed if initiating the biologic in patients with cardiovascular risk factors or history, say researchers
People at high cardiovascular risk might have greater odds of acute coronary syndrome or stroke in the first few months on ustekinumab, researchers warn after conducting a large observational study.
Patients with psoriasis or Crohn’s disease prescribed the biologic had greater likelihood of a severe cardiovascular (CV) event in the first six months on therapy if they already had CV risk factors or a history of atherothrombotic disease, they found.
